Lack of effectiveness of adherence counselling in reversing virological failure among patients on long-term antiretroviral therapy in rural Uganda

J Birungi 1, 2, Z Cui, 3 S Okoboi, 4 A Kapaata, 5 P Munderi, 5 C Mukajjanga, 1 M Nansumba, 3 MS Nyonyintono, 1 M Nanfuka, 1 J Kim, 6 J Zhu, 6 P Kaleebu 2 and DM Moore 3, 6

1 The AIDS Support Organisation (TASO), Kampala, Uganda, 2 Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine, Uganda Research Unit on AIDS, Entebbe, Uganda, 3 BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, 4 Infectious Diseases Institute, Makerere, Uganda, 5 International Association of Providers of AIDS Care, Washington, DC, USA and 6 University of British Columbia, Vancouver, BC, Canada

Objectives
The current World Health Organization and Uganda Ministry of Health HIV treatment guidelines recommend that asymptomatic patients who have a viral load (VL) \( \geq 1000 \) HIV-1 RNA copies/mL should receive adherence counselling and repeat VL testing before switching to second-line therapy. We evaluated the effectiveness of this strategy in a large HIV treatment programme of The AIDS Support Organisation Jinja in Jinja, Uganda.

Methods
We measured the HIV VL at enrolment, and for participants with VL \( \geq 1000 \) copies/mL we informed them of their result, offered enhanced adherence counselling and repeated the VL measurement after 3 months. All blood samples with VL \( \geq 1000 \) copies/mL were sequenced in the polymerase (pol) region, a 1257-bp fragment spanning the protease and reverse transcriptase genes.

Results
One thousand and ninety-one participants were enrolled in the study; 74.7% were female and the median age was 44 years [interquartile range (IQR) 39–50 years]. The median time on antiretroviral therapy (ART) at enrolment was 6.75 years [IQR 5.3–7.6 years] and the median CD4 cell count was 494 cells/\( \mu L \) [IQR 351–691 cells/\( \mu L \)]. A total of 113 participants (10.4%) had VLs \( \geq 1000 \) copies/mL and were informed of the VL result and its implications and given adherence counselling. Of these 113 participants, 102 completed 3 months of follow-up and 93 (91%) still had VLs \( \geq 1000 \) copies/mL. We successfully genotyped HIV for 105 patients (93%) and found that 103 (98%) had at least one mutation: eight (7.6%) had only one mutation, 94 (89.5%) had two mutations and one sample (1%) had three mutations.

Conclusions
In this study, enhanced adherence counselling was not effective in reversing virologically defined treatment failure for patients on long-term ART who had not previously had a VL test.

Keywords: adherence counselling, HIV, resource-limited setting, reversal, virological failure

Accepted 4 July 2019

Introduction
There has been a dramatic expansion of access to antiretroviral therapy (ART) in sub-Saharan Africa over the past two decades, with 21.7 million people accessing ART by the end of 2017 [1]. Until recently, most of this expanded access occurred through programmes that did not offer routine viral load (VL) monitoring, in keeping with earlier
guidance from the World Health Organization (WHO) which did not explicitly recommend VL testing for patients on ART in resource-limited settings [2,3]. This practice had been supported by the results of randomized clinical trials which found no added clinical benefit of the addition of routine VL monitoring for patients on ART when compared to CD4 cell count monitoring alone [4–7].

However, more recently, WHO guidelines for HIV care and treatment in resource-limited settings were revised to recommend routine VL testing as the preferred tool for diagnosing ART treatment failure [8] as it provides a more accurate indication of ART treatment failure and hence avoids unnecessary switches to second-line therapy [9,10]. It is also expected that treatment failure could be detected earlier and therefore should reduce the number and severity of drug-resistance mutations accumulated in patients who are failing therapy [10]. VL results can also help health care providers to differentiate between non-adherence and ART treatment failure caused by resistance [9]. Additionally, there have been recent findings from a systematic review indicating that clinical and immunological approaches for diagnosing treatment failure have low sensitivity and positive predictive value in identifying persons with virological failure [11].

Consequently, many national ART programmes in sub-Saharan African countries are now adopting the revised WHO recommendations and many programmes that did not provide VL testing may have begun using this as an additional monitoring tool. In sub-Saharan Africa, seven countries, South Africa, Tanzania, Côte d’Ivoire, Kenya, Malawi, Namibia and Uganda, are reported to be at various stages of scaling up routine VL monitoring [12].

In Uganda, the 2013 national ART treatment guidelines recommend that VL testing should be conducted 6 months after initiation of therapy and annually thereafter [13]. Both the WHO and the Ugandan ART guidelines recommend that asymptomatic patients who have been identified with VL ≥ 1000 copies/mL should be offered enhanced adherence counselling for 3–6 months and repeat VL testing before switching to second-line therapy [3,14]. Virological treatment failure is confirmed after two consecutive plasma VL test results ≥ 1000 copies/mL obtained 3–6 months apart, with enhanced adherence counselling and support following the first VL test [13,14].

However, little is known about the effectiveness of counselling and adherence support interventions in reversing virological failure in long-term HIV-positive patients, particularly in those who have been receiving ART for long periods of time without prior VL testing.

We designed a study to evaluate the effectiveness of enhanced adherence counselling and support for patients identified with VL ≥ 1000 copies/mL at their first VL test, among individuals who had been receiving ART for ≥ 4 years in an HIV treatment programme in which VL testing was not routinely available. Furthermore, we evaluated factors associated with successful reversal of virological failure, including ART drug resistance patterns, in these patients.

Methods

In June 2012, we initiated a prospective cohort study titled the Long-term Outcome on Antiretroviral Therapy Study in Uganda (LTOAU). This study recruited HIV-positive patients who were receiving care at The AIDS Support Organisation (TASO) Jinja service centre, and had been receiving ART for a minimum of 4 years.

The AIDS Support Organisation Jinja is one of the 11 HIV clinics of TASO, the largest nongovernmental organization in Uganda providing HIV care in the country. The TASO Jinja clinic is located in Jinja District, in the eastern-central region of Uganda, and serves persons in the district and other neighbouring districts within a radius of 75 km. Jinja District has a population of 468 256 and, like its neighbouring areas, is largely rural; the average annual income per household is estimated to be US$100, and the majority of inhabitants are subsistence farmers, with very few working in the formal sector and earning wages [15,16].

The ART programme in TASO Jinja began in 2004, and has over 5000 HIV-positive persons receiving therapy. All patients are commenced on ART in accordance with Ugandan national ART guidelines which recommend first-line regimens with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus one nonnucleoside reverse transcriptase inhibitor (NNRTI). Second-line regimens preferentially include two NRTIs not used in the first-line regimen and a protease inhibitor (PI), most commonly lopinavir-ritonavir. During the period of our study, VL monitoring was not provided routinely; however, immunological (CD4 cell count testing) and clinical monitoring was carried out every 6 months in accordance with the Ugandan national ART guidelines [13,14].

We recruited HIV-positive patients aged ≥ 18 years who had presented for clinical care at the TASO Jinja clinic or outreach sites between 1 July 2012 and 31 December 2013 and had been receiving first-line ART for ≥ 4 years. We excluded patients who had ever received a lopinavir-ritonavir-containing regimen.

From June 2012 to July 2013, we provided an information sheet about the proposed study to all TASO Jinja patients who had been receiving ART for a minimum of 4 years. After providing informed consent, participants completed an interviewer-administered questionnaire and
had blood drawn for VL and CD4 cell count testing. We collected clinical, demographic and behavioural data at the first study visit and all participants continued to receive routine care from the TASO clinical teams every 3 months. After August 2013, we further restricted enrolment to patients whose last CD4 cell count was \( \leq 450 \text{ cells/\mu L} \) and continued recruitment until January 2015. This restriction was decided upon following an interim analysis that demonstrated that the prevalence of virological failure among patients with a CD4 cell count of \( > 450 \text{ cells/\mu L} \) was \( < 2\% \). We therefore took this step to increase the diagnostic yield of identifying patients with VL \( \geq 1000 \text{ copies/mL} \).

We measured the HIV VL at enrolment and, for participants with a VL \( \geq 1000 \text{ copies/mL} \), we informed them of the result and its interpretation and offered enhanced adherence counselling. This consisted of additional monthly face-to-face sessions with the counsellor for three consecutive months. During this session, the counsellor discussed the implications of unsuppressed VL, established the patient’s adherence level, and, together with the patient, reviewed the previous adherence strategies to develop a revised adherence plan. Where possible, the ‘treatment buddies’ were re-contacted during this period. These participants then had a repeat VL measurement 3 months after the first test to determine if they still had virological failure.

In our study, if participants met the criteria for clinical failure, they were offered switches to second-line therapy after the first visit, but otherwise decisions about changing ART regimens (including decisions for patients with immunological failure) were deferred until after the 3 months of enhanced adherence counselling support. Additional social and behavioural data were collected at the 3-month study visit for those with virological failure.

Adherence was measured based on self-reported responses to two questions: (1) ‘In general, how often do you miss taking your ARV pills?’ (responses: never; once a month or less; more than once a month but less than once a week; and once a week or more) and (2) ‘In this past month how many of your ARV pills have you missed taking?’ (responses: 0, 1, 2, 3, 4, 5 and > 5).

HIV VL was measured with the COBAS Ampliprep/TaqMan HIV-1 test V2.0 (Roche, Mannheim, Germany) at the Uganda Virus Research Institute (UVRI)/Medical Research Council (UK) laboratory in Entebbe. All blood samples with a VL \( \geq 1000 \text{ copies/mL} \) were sequenced in the polymerase (pol) region, a 1257-bp fragment spanning the protease and reverse transcriptase genes, as previously described [17]. The study received approval from the Research Ethics Committee of UVRI, the Uganda National Council for Science and Technology in Uganda and the University of British Columbia in Vancouver, Canada.

Virological failure was defined as having a VL \( \geq 1000 \text{ copies/mL} \) at enrolment and after 3 months of enhanced adherence counselling support.

We obtained descriptive statistics of characteristics of the entire study population including those with VL \( \leq 1000 \text{ copies/mL} \) at enrolment and included all the explanatory and outcome variables of interest. As multiple thymidine analogue mutations (TAMs) have the greatest propensity to reduce the effectiveness of second-line regimens in use in low-income countries, we conducted bivariate analyses comparing participants who had zero or one TAM with those with at least two TAMs using Wilcoxon rank sum tests for continuous variables and \( \chi^2 \) or Fisher’s exact test for categorical variables. We then conducted a subsequent bivariate analysis comparing participants on the basis of correction of virological failure after an additional 3 months of follow-up. All analyses were conducted using SAS Version 9.3 (SAS Corporation, Cary, NC).

Results

A total of 1091 participants were enrolled in the study, of whom 815 (74.7%) were female, and the median age was 44 years [interquartile range (IQR) 39–50 years]. The median time on ART at enrolment was 6.7 years (IQR 5.3–7.6 years) and the median CD4 cell count at enrolment was 494 cells/\mu L (IQR 351–691 cells/\mu L). The most common regimen taken by participants at the time of enrolment in this study was nevirapine, lamivudine and zidovudine (72.7% of participants) followed by efavirenz, lamivudine and zidovudine (18.3%) and nevirapine, lamivudine and tenofovir (7.4%). However, 555 participants (50.9%) reported receiving other drug regimens since beginning ART. Of these, the most commonly received ART regimen was nevirapine, lamivudine and stavudine (407 participants or 73.3% of those with previous regimens). A total of 667 (61.3%) participants reported never missing a dose of their ART and 865 (79.6%) reported not missing any doses in the previous month (Table 1).

While we were unable to quantify the number of individuals who were ineligible for this study because of previous switches to lopinavir-containing ART regimens, by the end of 2014 (during our recruitment and enrolment period), there were approximately 265 clients of TASO Jinja who were receiving second-line therapy, out of approximately 5855 patients on ART [18].

Among the 1091 patients screened at enrolment, a total of 113 (10.4%) had VLs \( \geq 1000 \text{ copies/mL} \). Of these 1091 patients, 870 were enrolled irrespective of their CD4 cell counts, of whom 61 had virological failure (prevalence of 7.0%). The analysis comparing those participants in our study with VLs \( \geq 1000 \text{ copies/mL} \) to those with VLs
<1000 copies/mL is reported elsewhere [19]. When we restricted enrolment to those with CD4 cell counts ≤450 cells/μL, we found an additional 52 participants with virological failure out of 221 enrollees (prevalence of 23.5%).

For the 113 (61 plus 52) participants with HIV VL ≥1000 copies/mL at enrolment, we were able to successfully genotype 105 (93%) of the samples. Of these, 103 (98%) had at least one mutation, eight (7.6%) had only one mutation, 94 (89.5%) had two mutations and one sample (1%) had three mutations. A total of 100 samples (95.2%) had NRTI mutations and 98 (93.3%) had NNRTI mutations. Only one sample (1%) had a mutation conferring resistance to PIs. Among the 105 samples, M184V was the most frequent mutation found, occurring in 95 samples (90.5%), followed by Y181C which occurred in 42 samples (40.0%). A total of 12 samples (11.4%) had K65R mutations; 69 patients (65.7%) had at least one TAM and 53 (50.5%) had at least two TAMs (Table 2).

Having two or more TAMs was more common among participants with; <1 year of primary school education (24.5% of those with at least two TAMs versus 7.7% of those with zero or one TAM), previous regimen that included nevirapine, lamivudine and stavudine (96.0% vs. 62.5%; p=0.002) and an enrollment VL ≥100,000 copies/mL (43.4% vs. 26.9%; p=0.001). Participants with at least two TAMs also had lower CD4 cell counts at the first study visit (median of 179 versus 263 cells/μL in those with zero or one TAM; P=0.004) and had been receiving ART for a longer period of time (median of 6.8 versus 6.2 years, respectively; P=0.026) (Table 3).

All the 113 patients were informed of the VL result by the study nurse or physician and given enhanced adherence counselling and support by a counsellor. Of these, 102 completed follow-up at the 3-month study visit and 93 (91%) still had VL ≥1000 copies/mL after

### Table 1 Characteristics of the 1091 participants at their enrolment visit

| Characteristic              | Category       | n   | %   |
|-----------------------------|----------------|-----|-----|
| Gender                      |                |     |     |
| Female                      |                | 815 | 74.7|
| Male                        |                | 276 | 25.3|
| Income source               |                |     |     |
| Agriculture                 |                | 335 | 30.7|
| Wage/salaried employment    |                | 143 | 13.1|
| Crafts trade                |                | 66  | 6.1 |
| Petty trade                 |                | 276 | 25.3|
| None                        |                | 91  | 8.3 |
| Other                       |                | 180 | 16.5|
| Education level             |                |     |     |
| Low                         |                | 224 | 20.5|
| Medium                      |                | 493 | 45.2|
| High                        |                | 374 | 34.3|
| Marital status              |                |     |     |
| Legally married             |                | 188 | 17.2|
| Cohabiting                  |                | 269 | 24.7|
| Single/separated/divorced   |                | 220 | 20.2|
| Widowed                     |                | 41  | 3.8 |
| Years in TASO               |                |     |     |
| < 2 years                   |                | 10  | 0.9 |
| 2 to < 5 years              |                | 41  | 3.8 |
| ≥ 4 years                   |                | 1039| 95.3|
| ARV regimen at enrolment    |                |     |     |
| Efavirenz/3TC/TDF           |                | 21  | 1.9 |
| Efavirenz/3TC/ZDV           |                | 200 | 18.3|
| Nevirapine/3TC/TDF          |                | 81  | 7.4 |
| Nevirapine/3TC/ZDV          |                | 787 | 72.1|
| Other ARV regimen           |                | 2   | 0.2 |
| Been on previous ARV        |                |     |     |
| No                          |                | 536 | 49.1|
| Yes                         |                | 555 | 50.9|
| Previous ARV regimen        |                |     |     |
| Efavirenz/3TC/TDF           |                | 2   | 0.4 |
| Efavirenz/3TC/ZDV           |                | 27  | 4.9 |
| Nevirapine/3TC/TDF          |                | 52  | 4.9 |
| Nevirapine/3TC/TDF          |                | 8   | 1.4 |
| Nevirapine/3TC/ZDV          |                | 59  | 10.6|
| Nevirapine/3TC/d4T          |                | 407 | 37.3|
| ARV adherence: frequency of missing pills | | | |
| Never                       |                | 667 | 61.3|
| Once a month or less        |                | 269 | 24.7|
| More than once a week but less than once a month | | | |
| Once a week or more         |                | 67  | 6.2 |
| Number of ARV pills reported missing in past month | | | |
| One or more                 |                | 222 | 20.4|
| None                        |                | 865 | 79.6|
| Viral load ≥1000 copies/mL  |                |     |     |
| No                          |                | 978 | 89.6|
| Yes                         |                | 113 | 10.4|

ARV, antiretroviral; TASO, The AIDS Support Organisation; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine; d4T, stavudine.

© 2019 The Authors. *HIV Medicine* published by John Wiley & Sons Ltd on behalf of British HIV Association

Table 2 Frequency of antiretroviral therapy (ART) resistance mutations among participants with viral load ≥1000 copies/mL (n = 105)

| ART class mutations | n   | %   |
|---------------------|-----|-----|
| NNRTI resistance mutations | 98  | 93.3|
| PI resistance mutations | 1   | 1.0 |
| NRTI resistance mutations | 100 | 95.2|
| TAMs                | 69  | 65.7|
| Other NRTI resistance mutations | 31  | 29.5|

Individual mutations

| M184V | 95  | 90.5|
| Y181C | 42  | 40.0|
| K103N | 36  | 34.3|
| M41 I*| 34  | 32.4|
| T215V*| 30  | 28.6|
| K70R* | 25  | 23.8|
| G190A | 23  | 21.9|
| L210W*| 21  | 20.0|
| T215F*| 19  | 18.1|
| D67N* | 18  | 17.1|
| K219Q*| 15  | 14.3|
| K219E*| 13  | 12.4|
| K65R  | 12  | 11.4|
| K101E | 7   | 6.7 |
| P225H | 6   | 5.7 |
| Others | 33  | 31.4|

NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation.
3 months. Comparing the nine (8.8%) participants who achieved a VL < 1000 copies/mL on the second test with those who did not, we found that a lower proportion of them had two or more drug mutations (50% versus 93%, respectively; \( P = 0.010 \)), NNRTI drug resistance mutations (67% versus 95.5%, respectively; \( P = 0.046 \)) and NRTI resistance mutations (67% versus 98%, respectively; \( P = 0.019 \)). We also found that none of those who achieved virological suppression had two or more TAMs compared to 51% of participants who remained unsuppressed (\( P = 0.027 \)). Furthermore, fewer participants who achieved virological suppression had M184 mutations compared to those who remained unsuppressed (50% versus 95%, respectively; \( P = 0.005 \)). Of the nine participants, four (44%), who had a VL between 1000 and 5000 copies/mL, were able to reverse their virological failure. However, for participants with VL > 5000 copies/mL, enhanced adherence support did not achieve a reduction in VL of > 10% (Table 4).

Of the 11 participants who did not have a repeat VL test conducted at 3 months, three died before their 3-month visit, another four were switched to second-line therapy before their 3-month visit, one was lost to follow-up and another four were more than 1 month late for their repeat VL test. In total, 97 (86%) of those with virological failure were switched to second-line therapy either before or after their 3-month visit.

Discussion

In this study, enhanced adherence counselling was largely ineffective in reversing virologically defined treatment failure for patients on long-term ART (patients on ART for \( \geq 4 \) years) who had not previously had a VL test. Only
Table 4 Virological failure after 3 months of adherence counselling intervention

| Characteristic                                               | Category                           | No (n = 9) | Yes (n = 93) | P-value |
|--------------------------------------------------------------|------------------------------------|------------|--------------|---------|
| Age (years) [median (IQR)]                                   |                                    | 45 (36–52) | 41 (36–44)  | 0.193   |
| Gender [n (%)]                                               | Female                             | 7 (77.8)   | 70 (75.3)    | 1.000   |
| Male                                                         | 2 (22.2)                           | 23 (24.7)  |              |         |
| Income source [n (%)]                                        | Agriculture                        | 1 (11.1)   | 23 (24.7)    | 0.063   |
| Wage/ salaried employment                                   | 0 (0)                              | 21 (22.6)  |              |         |
| Crafts trade                                                | 1 (11.1)                           | 3 (3.2)    |              |         |
| Petty trade                                                  | 3 (33.3)                           | 30 (32.3)  |              |         |
| None                                                        | 2 (22.2)                           | 4 (4.3)    |              |         |
| Other                                                       | 2 (22.2)                           | 12 (12.9)  |              |         |
| Education [n (%)]                                           | Low                                | 2 (22.2)   | 13 (14.0)    | 0.212   |
| High                                                        | 1 (11.1)                           | 36 (38.7)  |              |         |
| ≥ 4 years in The AIDS Support Organisation [n (%)]           | No                                 | 1 (11.1)   | 6 (6.5)      | 0.487   |
|                                                            | Yes                                | 8 (88.9)   | 87 (93.6)    |         |
| CD4 at enrolment [median (IQR)]                             |                                    | 364 (308–423) | 220 (129–335) | 0.053   |
| Time on ARV at enrolment [months] [median (IQR)]            |                                    | 62 (57–90) | 79 (61–92)   | 0.942   |
| ARV regimen at enrolment [n (%)]                            | Efavirenz/3TC/TDF                  | 1 (11.1)   | 2 (2.2)      | 0.046   |
| Efavirenz/3TC/ZDV                                            | 3 (33.3)                           | 8 (8.6)    |              |         |
| Nevirapine/3TC/TDF                                          | 1 (11.1)                           | 13 (14.0)  |              |         |
| Nevirapine/3TC/ZDV                                          | 4 (44.4)                           | 70 (75.3)  |              |         |
| Been on previous ARV                                        | No                                 | 4 (44.4)   | 51 (54.8)    | 0.729   |
|                                                            | Yes                                | 5 (55.6)   | 42 (45.2)    |         |
| Previous ARV regimen [n = 47]                               | Efavirenz/3TC/ZDV                  | 1 (20)     | 2 (4.8)      | 0.123   |
| Efavirenz/3TC/4AT                                           | 0 (0)                              | 1 (2.4)    |              |         |
| Nevirapine/3TC/ZDV                                          | 2 (40)                             | 6 (14.3)   |              |         |
| Nevirapine/3TC/d4T                                          | 2 (40)                             | 33 (78.6)  |              |         |
| ARV adherence [n = 100]                                     | Never                              | 6 (66.7)   | 49 (53.9)    | 0.772   |
|                                                            | More than once a week but less than | 1 (11.1)   | 6 (6.6)      |         |
|                                                            | once a month                       |            |              |         |
|                                                            | More than once a month             | 2 (22.2)   | 31 (34.1)    |         |
| Good ARV adherence [n = 100]                                | No                                 | 3 (33.3)   | 20 (22.0)    | 0.426   |
|                                                            | Yes                                | 6 (66.7)   | 71 (78)      |         |
| Did not miss any pill in the past month                     |                                    |            |              |         |
| Frequency of medicine companions observations in 7 days before enrolment [median (IQR)] | 11 (7–14) | 7 (4–14) | 0.363 |
| Switching to second-line therapy [n = 93]                   | No                                 |            | 90 (96.8)    |         |
|                                                            | Yes                                | 3 (3.2)    |              |         |
| Baseline viral load [n (%)]                                 | 1000–5000 copies/mL                | 4 (44.4)   | 5 (5.8)      | < 0.001 |
| 5000–10 000 copies/mL                                       | 1 (11.1)                           | 8 (8.6)    |              |         |
| 10 000–50 000 copies/mL                                     | 4 (44.4)                           | 39 (41.9)  |              |         |
| 50 000–100 000 copies/mL                                    | 13 (14.0)                          |            |              |         |
| > 100 000 copies/mL                                         | 4 (44.4)                           | 28 (30.1)  |              |         |
| > 1000 [n (%)]                                              | Yes                                | 9 (100)    | 93 (100)     | n/a     |
| > 5000 [n (%)]                                              | Yes                                | 5 (55.6)   | 88 (94.6)    | 0.003   |
| > 10 000 [n (%)]                                            | Yes                                | 4 (44.4)   | 80 (86.0)    | 0.008   |
| > 50 000 [n (%)]                                            | Yes                                | 4 (44.4)   | 41 (44.1)    | 1.0000  |
| Any drug resistance mutations [n = 93]                      | Yes                                | 5 (83.3)   | 88 (100)     | 0.064   |
| Two or more drug class mutations [n (%)]                    | Yes                                | 3 (50)     | 82 (93.2)    | 0.010   |
| Any NNRTI drug resistance [n (%)]                           | Yes                                | 4 (66.7)   | 84 (95.5)    | 0.046   |
| Any PI mutation [n (%)]                                     | Yes                                | 1 (11.1)   | 1.1000      |         |
| Any NRTI mutation [n (%)]                                   | Yes                                | 4 (66.7)   | 86 (97.7)    | 0.019   |
| Any TAM [n (%)]                                             | Yes                                | 2 (33.3)   | 58 (65.9)    | 0.185   |
| ≥ 2 TAMs [n (%)]                                            | Yes                                | 0 (0)      | 45 (51.1)    | 0.027   |
| Any other NRTI mutation [n (%)]                             | Yes                                | 2 (33.3)   | 28 (31.8)    | 1.0000  |
| K65R mutation [n (%)]                                       | Yes                                | 1 (16.7)   | 11 (12.5)    | 0.570   |
| M184V mutation [n (%)]                                      | Yes                                | 3 (50.0)   | 84 (95.5)    | 0.0047  |

ARV, antiretroviral; IQR, interquartile range; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine; d4T, stavudine; NRTI, nucleotide reverse transcriptase inhibitor; NNRTI, nucleotide reverse transcriptase inhibitor; TAM, thymidine analogue mutation.
9% of the participants who were found to have a VL of \( \geq 1000 \) copies/mL at enrolment were able to achieve a VL of \(< 1000 \) copies/mL after 3 months of enhanced adherence counselling and support. These results suggest that current national and international guidelines recommending that enhanced adherence counselling and repeat VL testing be offered to such patients on long-term ART should be reconsidered. Switching patients who have been receiving ART for long periods of time on the basis of a single VL result would probably result in more rapid reversal of virological failure and a much shorter duration of unsuppressed viraemia and reduced potential transmission of drug-resistant virus. Our study also found a high frequency of NRTI and NNRTI resistance mutations among the participants with virological failure, with M184V being the most common followed by Y181C. This is similar to what has been reported in other studies [20–22].

We also noted a very high prevalence of TAMs, with 65% of those with virological failure having at least one TAM and 50% having two or more TAMs; similar prevalences have been reported in other studies for patients receiving regimens containing stavudine, zidovudine, lamivudine, efavirenz and nevirapine [22–24]. However, a lower prevalence of TAMs of between 5 and 25% has been reported in a retrospective multicentre cohort study in sub-Saharan Africa among patients using tenofovir [25]. As many second-line regimens in sub-Saharan Africa will by necessity include didanosine and abacavir, which can have reduced effectiveness in the presence of increasing numbers of TAMs [26], these are probably the most concerning mutation patterns we found. Previous exposure to stavudine was associated with having two or more TAMs in our study. However, given that stavudine is no longer being prescribed in Uganda [13,27] and in most resource-limited settings in accordance with the WHO ART guidelines [8], this issue will probably be less of a problem in the future, which is somewhat reassuring. Fortunately, we also found a fairly low prevalence of the K65R mutation (in 11% of individuals with virological failure), which is another NRTI resistance mutation that can confer pan-NRTI resistance, although one study reported that K65R mutations are likely to increase with increased use of tenofovir as a first-line option [17]. VL measurement with enhanced adherence counselling has been demonstrated to be effective for individuals who are in the first few years of ART in South Africa [20,28,29]. However, our findings regarding adherence counselling for patients who had been receiving ART for longer periods of \( \geq 4 \) years are similar to the findings from a study in Swaziland which reported that, among patients receiving ART for a median of 2.9 years (IQR 1.6–4.6 years), those who were found to have raised VLs (VL \( \geq 1000 \) copies/mL) and received enhanced adherence counselling by counsellors were no more likely to achieve VL suppression at subsequent VL test than those who did not receive counselling [30]. Another study in Khayelitsha in South Africa reported higher rates of virological re-suppression among patients failing on second-line ART following enhanced adherence support [31]. However, patients in this study had been on second-line ART for a short period of time, a median of 1.7 years (IQR 0.9–2.5 years), and were using lopinavir-based second-line therapy rather than NNRTI-based first-line therapy. A systematic review of 29 studies on rates of emergence of HIV drug resistance in resource-limited settings revealed that the rates increased steadily with time on ART. Enhanced adherence counselling may not be effective in situations where virological failure is likely to have occurred months or years before diagnosis, and patients will probably already have developed resistance mutations that even good adherence may not overcome. It is worth noting that, in our study, in cases where virological failure was reversed, the initial median VL was < 1 000 copies/mL and CD4 cell counts tended to be higher.

The occurrence of three deaths in the 3-month period between the first and second VL results implies that mortality may be quite high among this population. While it is not clear whether switching medications earlier would have prevented these deaths, it is also not known if more deaths would have occurred had the study used the recommended upper limit of 6 months for the period between the two results, according to Uganda MoH ART guidelines [13,14].

This study had a number of limitations. Firstly, adherence measures were self-reported and could reflect underestimates of true nonadherence, as has been reported in studies elsewhere [32]. However, adherence to therapy among participants in this study must have been sufficient to allow participants to survive \( \geq 4 \) years on ART. Secondly, while we had a relatively large sample size of patients on long-term ART (> 1000), the proportion of those with virological failure was quite low at 7.0%, leaving a fairly small sample in which to study the effect of enhanced adherence counselling. This ‘limitation’, however, again demonstrates that TASO has done an excellent job in promoting ART adherence among programme participants. Programmes with greater proportions of nonadherent participants and those with treatment failure may find more value in promoting adherence. However, given the persistent impact of the NNRTI and NRTI resistance mutations that develop among individuals failing first-line therapy, this may not, in fact, be true.
In conclusion, our study found that enhanced adherence counselling was not effective in reversing virologically defined treatment failure for patients on long-term ART who had not previously had a VL test. Thus, recommendations that all patients with virological failure should undergo a period of enhanced counselling and re-measuring of VL before changing their therapy should be revisited. Our findings also highlight the need for timely HIV resistance testing for patients receiving ART in sub-Saharan Africa with unsuppressed VL at first measurement. It remains to be seen whether the resistance patterns we observed in this cohort will impact the longer term clinical and virological outcomes of these patients.

Acknowledgements

The authors would like to thank the study staff and participants in the Long Term Outcomes Study, as well as the staff at TASO-Jinja and the senior management at TASO headquarters. The study was funded by the Canadian Institutes for Health Research (Grant number MOP-119369). JB as a scholar of implementation science received support by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW010037. DMM is supported by a Scholar Award from the Michael Smith Foundation for Health Research.

References

1 UNAIDS. Global AIDS Update [Internet]. 2018. Available at http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2018_en.pdf (accessed 30 March, 2019).

2 World Health Organisation. Rapid advice: use of antiretroviral drugs for treating Pregnant women and preventing HIV infection in infants [Internet]. Geneva, Switzerland, WHO Press, 2009. Available at http://www.who.int/hiv/pub/mtct/rapid_advice_mtct.pdf (accessed 30 March, 2019).

3 World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach June 2013. [Internet]. 2013. Available at http://www.who.int/hiv/pub/guidelines/arv2013/en/(accessed 30 March, 2019).

4 Mermin J, Ekwaru JP, Were W, Coutinho A, Solberg P, Alexander LN. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343: d6792.

5 Jourdain G, Le Cœur S, Ngo-giang-huong N et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med 2013; 10: e1001494.

6 Laurent C, Kouanfack C, Laborde-balen G et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11: 825–833.

7 Kahn JG, Marseille E, Moore D, Ekwaru P, Kaharuza F, Mermin J. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost. BMJ 2011; 343: d6884.

8 World Health Organisation. March 2014 Supplement to the 2013 consolidated guidelines on use of Antiretroviral drugs for treating and preventing HIV infection. Recommendation for a Public health approach [Internet]. 2014. Available at www.who.int (accessed 30 March, 2019).

9 Orrell C, Harling G, Lawn SD, Kaplan R, McNally M. Conservation of first-line antiretroviral treatment. Antivir Ther 2007; 12: 83–88.

10 Sigaloff KC, Hamers RL, Wallis CL et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58: 5823–5831.

11 Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato MDM. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 World Health Organization criteria for virologic failure. AIDS 2014; 28(Suppl 2): 25161-9.

12 US Department for Health/Centres for Diseases Control. Morbidity and Mortality Weekly Report. Vol. 64 No. 46, 2015: 1287–1290.

13 Uganda Ministry of Health. Addendum to the National Antiretroviral treatment guidelines, 2013.

14 Uganda Ministry of Health: Kampala Consolidated guidelines for prevention and treatment of HIV in Uganda. Kampala, 2018.

15 Uganda Bureau of Statistics. The National Population and Housing Census 2014 Main Report. Kampala, Uganda [Internet]. 2014: 20. Available at http://www.ubos.org/onlinefiles/uploads/ubos/NPHC/ (accessed 30 March, 2019).

16 Visiting Uganda.com. Visiting Uganda: Jinja [Internet]. Jinja, 2000. Available at http://www.visiting-uganda.com/places/jinja.html (accessed 30 March, 2019).

17 Kaleebu P, Kirungi W, Watera C et al. Virological response and antiretroviral drug resistance emerging during antiretroviral therapy at three treatment centers in Uganda. PLoS ONE 2015; 10: e0145536.

18 The AIDS Support Organisation S. The AIDS Support Organisation Annual report 2014 [Internet]. Kampala: TTB investments, 2014. Available at http://www.tasouganda.org/index.php/publications/reports (accessed 30 March, 2019).
Okoboi S, Ding E, Persuad S et al. Community-based ART distribution system can effectively facilitate long-term program retention and low rates of death and virologic failure in rural Uganda. *AIDS Res Ther* 2015; 12: 37.

Hoffmann CJ, Charalambous S, Sim J et al. Viremia, resuppression and time to resistance in HIV subtype C during first line antiretroviral therapy in South Africa. *Clin Infect Dis* 2010; 49: 1928–1935.

Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. *J Infect Dis* 2013; 207 (Suppl 2): S49–S56.

Marconi VC, Sunpath H, Lu Z et al. Prevalence of HIV-1 drug resistance after failure of first Highly Active Antiretroviral regimen in KwaZulu Natal, South Africa. *Clin Infect Dis* 2008; 46: 1589–1597.

Goodall RL, Dunn DT, Nkurunziza P et al. Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. *J Antimicrob Chemother* 2017; 1450–1455.

Sigaloff KCE, Ramatsebe T, Viana R, Wit TFR, Wallis CL, Stevens WS. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. *AIDS Res Hum Retroviruses* 2012; 28: 171–175.

Gregson J, Kaleebu P, Marconi VC et al. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub-Saharan Africa: a retrospective multi-centre cohort study. *Lancet Infect Dis* [Internet] 2017; 17: 296–304.

White KL, Margot NA, Win T, Petropoulos CJ, Miller MD, Naegel LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R and M184V and their effects on enzyme function and viral replication capacity. *Antimicrob Agents Chemother* 2002; 46: 3437–3446.

Duber HC, Dansereau E, Masters SH et al. Uptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia. *PLoS ONE* 2015; 10: e0120350.

Gupta RK, Goodall RL, Ranopa M, Kityo C. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. *Clin Infect Dis* 2014; 58: 1023–1026.

Coetsee D, Boule A, Hildebrand K, Asselman V, Van Cutsem G, Goemaere E. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. *AIDS*. 2004; 18: (Suppl 3):S2: S27–S31.

Johanputra K, Parker LA, Azih C et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. *PLoS ONE* 2015; 10: e0116144.

Garone DB, Conradie K, Patten G et al. High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: A model of care in Khayelitsha, South Africa. *S Afri J HIV Med* 2013; 14: 166–169.

Erb S, Letang E, Glass TR et al. Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. *HIV Med* 2017; 18: 623–634.